๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Efficacy and Safety of Atazanavir in Patients with End-Stage Liver Disease

โœ Scribed by G. Guaraldi; S. Cocchi; A. Motta; S. Ciaffi; M. Codeluppi; S. Bonora; F. Di Benedetto; M. Masetti; M. Floridia; S. Baroncelli; D. Pinetti; A. Bertolini; G. E. Gerunda; R. Esposito

Book ID
107705724
Publisher
Springer-Verlag
Year
2009
Tongue
English
Weight
236 KB
Volume
37
Category
Article
ISSN
0300-8126

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Safety of invasive procedures in end-sta
Safety of invasive procedures in end-stage liver disease patients
โœ James D. Perkins ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB ๐Ÿ‘ 1 views

Patients with end-stage liver disease (ESLD) are predisposed to bleeding complications due to thrombocytopenia, reduced synthesis of coagulation factors, and increased fibrinolytic activity. The exact incidence of vascular access site and bleeding complications related to cardiac catheterization in

Feasibility and safety of percutaneous c
Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation
โœ Babak Azarbal; Paul Poommipanit; Boris Arbit; Antoine Hage; Jignesh Patel; Miche ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB ๐Ÿ‘ 1 views

Percutaneous coronary intervention (PCI) has traditionally not been an option for patients with end-stage liver disease (ESLD) and coronary artery disease (CAD). This retrospective study was designed to demonstrate the feasibility and safety of PCI in liver transplant candidates. Patients with ESLD